Compare OCG & PFSA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | OCG | PFSA |
|---|---|---|
| Founded | 2018 | 2009 |
| Country | Hong Kong | United States |
| Employees | N/A | N/A |
| Industry | Other Consumer Services | Medical/Dental Instruments |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.8M | 3.7M |
| IPO Year | 2019 | N/A |
| Metric | OCG | PFSA |
|---|---|---|
| Price | $0.67 | $0.90 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 450.5K | 288.1K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | ★ 7.63% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.01 | $0.05 |
| 52 Week High | $19.29 | $4.22 |
| Indicator | OCG | PFSA |
|---|---|---|
| Relative Strength Index (RSI) | 39.02 | 44.72 |
| Support Level | $0.04 | $0.16 |
| Resistance Level | $4.24 | $2.22 |
| Average True Range (ATR) | 0.10 | 0.19 |
| MACD | -0.02 | -0.13 |
| Stochastic Oscillator | 11.14 | 3.82 |
Oriental Culture Holding Ltd is an online provider of collectibles and artwork e-commerce services. The company also offers online and offline integrated marketing, storage, and technical maintenance services to customers. The company operates through one segment, namely, e-commerce of artwork trading. It generates revenue through listing service fees, transaction fees, and other revenues collected from traders.
Profusa Inc is a clinical-stage digital health and medical technology company focused on developing biosensing solutions to improve health outcomes for patients with a variety of different diseases and conditions. The Company's technology enables the development of bioengineered sensors that are designed to become one with the body to detect and continuously transmit actionable, clinical-grade data for personal and medical use. The Company's first offering in the European Union, the Lumee Oxygen Platform, is designed to report reliable tissue oxygen levels at various regions of interest, both acutely and long-term.